PolyActiva Announces First Patient Enrolled in US Phase 2b Clinical Trial of its Ocular Micro Implant for Glaucoma and Ocular Hypertension

FORT WORTH, Texas & MELBOURNE, Australia--(BUSINESS WIRE)--PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced that the first U.S. patient has been enrolled in the company’s Phase 2b clinical trial evaluating PA5108, an investigational, new chemical entity (NCE), intracameral ocular micro implant, for the reduction in intraocular pressure (IOP) for patients with primary open-a